Integration of endocrine therapy with targeted agents

Breast Cancer Research

Volumn 10, Issue SUPPL. 4, 2008, Pages

  Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR;

ARTICLE; BREAST TUMOR; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENES, ERBB-2; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 60749094210     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2180     Document Type: Article

References (29)

1. Johnston SRD. Hormone resistance. Hormone Receptors in Breast Cancer 2008, New York, NY: Springer Science, Fuqua SAW, .
2. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
3. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006, 66:8266-8273. 10.1158/0008-5472.CAN-05-4045, 16912207.
4. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993, 106:1377-1388.
5. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87:746-750. 10.1093/jnci/87.10.746, 7563152.
6. Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007, 18:64-69. 10.1093/annonc/mdl341, 17030543.
7. Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Gnant MF, Jakesz R, Zielinski CC. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single centre experience. Eur J Cancer 2005, 41:2655-2661. 10.1016/j.ejca.2005.07.016, 16230005.
8. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, . North Central Cancer Treatment Group Trial N0032 Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006, 24:1052-1056. 10.1200/JCO.2005.04.1053, 16505423, North Central Cancer Treatment Group Trial N0032.
9. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670. 10.1200/JCO.2007.13.5822, 18316794.
10. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003, 95:1597-1608.
11. Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005, 12:1017-1036. 10.1677/erc.1.00905, 16322340.
12. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005, 65:5439-5444. 10.1158/0008-5472.CAN-04-2782, 15958593.
13. Johnston SR, Leary A, Martin LA, Smith IE, Dowsett M. Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?. Cancer 2008, 112:710-717. 10.1002/cncr.23190, 18072235.
14. Osborne K, Neven P, Dirix L, Mackey J, Robert J, Underhill C, Gutierrez C, Magill P, Hargreaves L. Randomized Phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer [abstract]. Breast Cancer Res Treat 2007, 106(suppl 1):2067.
15. Cristofanilli M, Valero V, Mangalik A, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Magill P. A phase II multicenter, double-blind, randomised trial to compare anastrozole plus gefitinib with anastrozole plus placebo in post-menopausal women with hormone recptor positive metastatic breast cancer [abstract 1012]. Proc Am Soc Clin Oncol 2008, 26:15S.
16. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-1359. 10.1210/me.15.8.1344, 11463858.
17. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nolè F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006, 8:R4. 1413988, 16417653, 10.1186/bcr1366.
18. Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007, 102:43-49. 10.1007/s10549-006-9307-8, 16897431.
19. Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer [abstract]. Breast Cancer Res Treat 2006, 100(suppl 1):3.
20. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006, 103:7795-7800. 1472524, 16682622, 10.1073/pnas.0602468103.
21. AF Martin LA, Lykkesfeldt AE, Dowsett M, Johnston SRD. Enhancing endocrine responsiveness using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in cell models of endocrine resistance [abstract]. Breast Cancer Res Treat 2006, 100(suppl 1):303.
22. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65:18-25.
23. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003, 21:1967-1972. 10.1200/JCO.2003.09.098, 12743150.
24. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, Trink B, Sidransky D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005, 7:R609-R616. 1242128, 16168105, 10.1186/bcr1262.
25. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 3:772-775.
26. Baselga J, Roché H, Fumoleau P, Campone M, Colomer R, Cortes-Funes H, Gil M, Chan S, Boni J, Kong S, Cincotta M, Moore L. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract]. Breast Cancer Res Treat 2005, 94(suppl 1):1068.
27. Chow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. Breast Cancer Res Treat 2006, 100(suppl 1):6091.
28. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Dixon JM, Jonat W, Rugo HS. Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER+ breast cancer [abstract]. Breast Cancer Res Treat 2007, 106(suppl 1):2066.
29. Gardner H, Bandaru R, Barrett C, Calcaterra M, Crowell T, Decker J, Dixon M, Fisch R, Fuchs M, Gelb A, Hanoteau N, Jonat W, Lane H, Lebwohl D, Liu W-H, Molloy B, Pena C, Phillips P, Rheinhardt J, Rugo H, Salesky S, Steinseifer J, Stumm M, Tokaji E, Voelker F, Yarbrough G, Yateman N, Yu Y, Zuber E, Baselga J. Biomarker analysis of a phase II double-blind randomised trial of daily oral RAD001 (Everolimus) plus letrozole or placebo plus letrozole as neoadjuvant therapy for patients with estrogen receptor positive breast cancer [abstract]. Breast Cancer Res Treat 2007, 106(suppl 1):4006.